Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.

ID: ALA4138072

Journal: Medchemcomm

Title: Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.

Authors: Luo LX, Fan XX, Li Y, Peng X, Ji YC, Hsiao WW, Liu L, Leung EL, Yao XJ.

Abstract: Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.

CiteXplore: 30108778

DOI: 10.1039/C6MD00643D

Patent ID: ┄